▎ 摘　　要

Research has commonly utilized graphene-based drug delivery systems for a long time to achieve effective cancer treatment. In the present study, doxorubicin (DOX) and selective estrogen receptor modulator tamoxifen (TAM) anticancer drugs used in breast cancer treatment were bound to a graphene oxide (GO)-based and folic acid (FA)-targeted nanocarrier system that was made biocompatible with chitosan (CS). To this end, graphene oxide synthesis was primarily carried out by employing the modified Hummer's method, and then FA and CS were loaded on GO to obtain a targeted and biocompatible carrier The characterization of the obtained conjugate was performed by X-ray diffraction analysis, Fourier transform infrared spectroscopy, UV-visible spectrophotometry, scanning electron microscopy, and zeta potential analysis. The zeta potential values of all samples were checked and all of them have a zeta potential above the stability value of +/- 25 mV. GO-CS-FA has the highest zeta potential of 68.8 mV. The graphene oxide-chitosan-folic acid-tamoxifen-doxorubicin (GO-CS-FA-TAM-DOX) nanocarrier-based drug displayed a pH-dependent drug release. The drug release profile from these systems was researched in two pH buffer solutions prepared as acidic (pH 5.8) and physiological (pH 7.4). The characterization analyses showed that the drugs bound successfully to the targeted delivery system. The drug release analyses demonstrated that GO-CS-FA-TAM-DOX was released better in the acidic (pH 5.8) medium compared to the physiological (pH 7.4) medium after 24 h.